FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Ccl Industries Inc.

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target by CAD4 to CAD98 on an EV/EBITDA of 11x our 2026 EBITDA forecast, a premium to its five-year average forward EV/EBITDA of 10.0x. We raise our 2026 EPS view to CAD4.90 from CAD4.89 and 2027 to CAD5.31 from CAD5.27. We maintain our Strong Buy opinion following Q1 results that beat EPS estimates. Q1 organic sales grew 3.1% with solid performance across Design, Secure, and Healthcare/Specialty segments, along with a recovery in food and beverage packaging. Although management flagged resin and aluminum inflation, we think CCL Industries is well positioned to pass through pricing. Relief from Section 232 tariffs benefited U.S. operations in Q1 and could be an additional tailwind through 2026 by reducing upward pressure on aluminum prices. The company generates consistent cash flow from operations ($37.3M in Q1 2026), allowing strategic flexibility for share repurchases and bolt-on M&A.

Related Articles

Research

Research Alert: CFRA Lowers Rating On Shares Of Medtronic Plc To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target to $83 from $118, 13.7x our FY 27 (Apr.) EPS view, below MDT's 10-year historical forward average of 17.6x. We trim our FY 26 EPS estimate to $5.52 from $5.65 due to lower profitability expectations and MiniMed IPO dilution. We cut our FY 27 view to $6.06 from $6.11. We downgrade shares to Hold from Buy following a mixed Q1 MedTech earnings season, with divergent performances across companies and multiple near-term headwinds, including margin pressures from rising raw material costs, supply chain challenges, and tariffs, which we think can also impact MDT. Adding to these pressures, MDT announced (May 11) the closure of its Santa Rosa, CA facility, which faced a $381M antitrust verdict in February. Also, the China business (~10% of total revenue) has been facing challenges from aggressive anti-corruption campaigns targeting health care and government volume-based procurement policies, triggering steep price cuts on medical devices, with limited near-term visibility on normalization.

$MDT
Research

CCL Industries Target Raised To C$104 From $102, Keeps Outperform at National Bk; Notes Q1 Revs In Line, EBITDA Slightly Better, Optimistic Outlook, Layering In NCIB Assumptions

Price: $86.86, Change: $+2.40, Percent Change: +2.84%

$CCL-A.TO$CCL-B.TO
Research

Research Alert: CFRA Maintains Hold Opinion On Ads Of Honda Motor Co., Ltd

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We revise our 12-month target price to USD26 (from USD25), which implies a forward P/E of 9.7x based on our revised FY 27 (Mar.) EPS estimate of JPY423 (up from JPY297). We also initiate our FY 28 EPS estimate of JPY579. Our upward revision reflects a clearer near-term earnings trough following Honda's decisive reassessment of its automobile electrification strategy, which resulted in total EV-related losses in FY 26 but allows the company to focus on its profitable hybrid electric vehicle (HEV) and motorcycle operations. The motorcycle business continues to deliver record-high sales volumes and operating profit, supported by strong demand in India and Brazil, while the automobile business is projected to benefit from a renewed focus on HEVs, particularly in North America, where the company plans to increase production and introduce new models. Honda's sound financial foundation supports a stable dividend.

$HMC